Table 1.
Characteristics of the study group of proteinuric patients with T1D and CKD stages 1–3 according to availability of a measure of postbaseline glycemia
| Characteristic | Complete Cohort (n=279) | Rapid Progressors (n=30) | Nonattenders (n=40) |
|---|---|---|---|
| Women, n (%) | 124 (44.4) | 18 (60.0) | 15 (37.5) |
| Age (yr) | 38 (32, 44) | 37 (33, 43) | 36 (33, 42) |
| Diabetes duration (yr) | 24 (19, 31) | 22 (18, 26) | 25 (20, 32) |
| Duration of care at Joslin Clinic (yr) | 19 (10, 28) | 16 (10, 23) | 18 (13, 24) |
| ACR (mg/g) | 687 (441, 1244) | 2665 (883, 3944) | 809 (535, 1560) |
| Serum creatinine (mg/dl) | 1.00 (0.79, 1.28) | 1.65 (1.38, 1.95) | 1.12 (0.93, 1.45) |
| eGFR (ml/min per 1.73 m2) | 85 (64, 110) | 41 (36, 51) | 77 (55, 98) |
| Systolic BP (mmHg) | 130 (120, 142) | 133 (120, 144) | 133 (128, 145) |
| Diastolic BP (mmHg) | 78 (70, 84) | 79 (70, 85) | 82 (77, 86) |
| Treatment with ACEI or ARBa | 194 (69.5%) | 18 (60.0%) | 28 (70.0%) |
| Prebaseline HbA1c (%)b | 9.3 (8.4, 10.4) | 10.1 (8.9, 11.6) | 8.8 (7.8, 9.7) |
| Postbaseline HbA1c (%)c | 8.7 (7.8, 9.8) | – | – |
| No. of prebaseline HbA1c measures per patient | 7 (3, 10) | 6 (2, 11) | 2 (1, 5) |
| No. of postbaseline HbA1c measures per patient | 7 (2, 12) | – | – |
| Follow-up (yr) | 10.2 (7.8, 14.5) | 1.9 (1.5, 2.0) | 9.6 (6.5, 11.2) |
| Incidence rate of ESRD/100 patient-years (n) | 2.7 (77) | 55.5 (30) | 4.9 (18) |
| Non-ESRD mortality/100 patient-years (n) | 0.8 (23) | 0 (0) | 1.6 (6) |
| No. of eGFR values per patient | 11 (5, 23) | 3 (2, 10) | 2 (2, 3) |
| eGFR values per year | 1.2 (0.5, 2.3) | 2.0 (1.0, 5.8) | 0.3 (0.2, 0.4) |
Data are median (first, third quartiles) or number (percentage). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker.
a
Prevalence of renoprotection was 55% in patients entering study in 1991–1995, 61% in 1996–2000, and 82% in 2001–2004.1
b
Time-weighted average HbA1c during 5 years up to and including enrollment examination.
c
Time-weighted average HbA1c during first half of each individual’s follow-up interval. The median (first, third quartiles) length of these half-intervals of follow-up was 5.1 years (3.9, 7.3).